Last reviewed · How we verify
glycopyrrolate, 1.0%
At a glance
| Generic name | glycopyrrolate, 1.0% |
|---|---|
| Also known as | DRM04B |
| Sponsor | Journey Medical Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Sugammadex To IMprove Bowel Function (PHASE4)
- Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery (PHASE4)
- Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions (PHASE2)
- A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis (PHASE2)
- The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glycopyrrolate, 1.0% CI brief — competitive landscape report
- glycopyrrolate, 1.0% updates RSS · CI watch RSS
- Journey Medical Corporation portfolio CI